(Q39816362)

14 September 2017

title

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects (English)

1 reference

14 September 2017

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27121669%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Leo Seman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27121669%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Sreeraj Macha

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27121669%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Gudrun Simons

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27121669%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Bailuo Ren

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27121669%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Sabine Pinnetti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27121669%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Hans J Woerle

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27121669%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Klaus Dugi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27121669%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

27 March 2013

1 reference

Clinical pharmacology in drug development

14 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27121669%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27121669%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27121669%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

152-161

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27121669%20AND%20SRC:MED&resulttype=core&format=json

Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey

4 June 2020

cites work

1 reference

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

21 January 2018

1 reference

Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program

21 January 2018

1 reference

The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

21 January 2018

1 reference

Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going

21 January 2018

1 reference

Effect of aging on glucose homeostasis: accelerated deterioration of beta-cell function in individuals with impaired glucose tolerance

21 January 2018

1 reference

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

21 January 2018

1 reference

Renal gluconeogenesis: its importance in human glucose homeostasis

21 January 2018

1 reference

Renal compensation for impaired hepatic glucose release during hypoglycemia in type 2 diabetes: further evidence for hepatorenal reciprocity

21 January 2018

1 reference

Glucose handling by the kidney

21 January 2018

1 reference

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

21 January 2018

1 reference

Effect of kidney disease on glucose handling (including genetic defects).

21 January 2018

1 reference

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

21 January 2018

1 reference

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

21 January 2018

1 reference

Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.

21 January 2018

1 reference

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

21 January 2018

1 reference

Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

21 January 2018

1 reference

21 January 2018

Learning from glycosuria

1 reference

Glucagon regulation of energy metabolism

21 January 2018

1 reference

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

Effect of non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CPDD.16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27121669%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference